Healio: Asundexian did not prevent stroke, systemic embolism vs. apixaban in atrial fibrillation Please provide your email address to receive an email when new articles are posted on . Asundexian did not prevent stroke or systemic embolism vs.

Understanding the Context

apixaban in patients with atrial fibrillation despite ... Asundexian did not prevent stroke, systemic embolism vs. apixaban in atrial fibrillation BOSTON, MA—Patients who develop thrombus on the Watchman left atrial appendage (LAA) closure device (Boston Scientific) carry a greater risk of stroke or systemic embolism, and there are hints of a ... Patent foramen ovale (PFO) increase the rate of ischemic stroke among patients with symptomatic pulmonary embolism (PE), according to a new prospective cohort study.

Key Insights

Its authors say the findings ... National Institute for Health and Care Excellence: Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation FiercePharma: FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events RARITAN, NJ, – Janssen Pharmaceuticals, Inc. FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events Patients with acute pulmonary embolism (PE) are at high risk for stroke, and the risk is further raised by about fourfold by the presence of a patent foramen ovale (PFO), a new study suggests. "This ... National Institute for Health and Care Excellence: Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism